Additionally, MXD3 can impede the invasion of T-cells, which in turn promotes immunological evasion of tumors.[30] They discovered that increased MXD3 leads to an increase in the AR signaling pathway, which in turn contributes to the development of hepatocarcinogenesis.[31] A signature that includes MXD3 has been established by Ma et al, and it has demonstrated good performance in prognosis prediction.[32,33] This is despite the limited evidence regarding the biological roles that MXD3 plays in PRAD. The gene discussed is MXD3; the disease is prostate adenocarcinoma.